A two cohort, ascending dose study of intra-tumoral MTX110 in patients with recurrent glioblastoma. With the aim to assess the safety and also the recommended phase 2 dose of MTX110.~The patient will undergo a surgical procedure to insert a programmable pump and catheter system to allow administration of MTX110 directly to the tumour. The patient will receive one of up to a potential three doses of MTX110 either as monotherapy (cohort A) or combined with lomustine (cohort B). This will be based on an accelerated dose titration/3+3 design.
A study designed to assess the safety of MTX110 alone and in combination with lomustine for patients suffering with recurrent glioblastoma. MTX110 will be administered directly to the site of the tumour via a catheter which is inserted during a surgical procedure at the beginning of the study.